Last Updated: 08/10/2025
Development and characterization of murine monoclonal antibodies against allelic variants of the Plasmodium vivax circumsporozoite protein (VK210, VK247 and Pv-like) and its C-terminal region
Objectives
This study aims to produce and characterize murine monoclonal antibodies against these three allelic variants of CSP and against the conserved C-terminal region of the protein. C57BL/6 mice will be immunized with recombinant proteins containing the allelic variants of CSP.
Malaria caused by Plasmodium vivax (P. vivax) is widespread in several regions of the world, representing a challenge for disease control. The circumsporozoite protein (CSP), present on the surface of P. vivax sporozoites, plays a crucial role in hepatocyte invasion. However, the allelic variants of CSP, called VK210, VK247 and P. vivax-like, have distinct sequences that hinder the development of universal vaccines. Based on the animals’ immune response, using the hybridoma technique, monoclonal antibodies will be produced and then undergo purification and characterization processes to assess their specificity and affinity for the target proteins. Tests such as ELISA, Western Blot and Dot Blot will be performed to determine the specificity of the antibodies generated and characterize them. The antibodies produced in this study may serve as quality control tools in the development of CSP-based vaccines, in addition to enabling additional studies on the immune response against the different variants of P. vivax, contributing to progress in the fight against vivax malaria.
Mar 2025 — Dec 2025
Related Resources
